Indivior Pharmaceuticals, Inc. (INDV) 8-K Current Report: March 17, 2026
Filed: March 17, 2026
Health Care
Pharmaceutical PreparationsIndivior Pharmaceuticals, Inc. (INDV) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 1.02: Termination of a Material Definitive Agreement
Indivior Pharmaceuticals, Inc. 8-K Mar 17, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Indivior issued convertible notes (144A private placement) to qualified institutional buyers — not publicly offered
- • Max 16,202,200 common shares issuable upon conversion, representing meaningful potential dilution
- • Initial max conversion rate of 32.4044 shares per $1,000 principal — conversion price implied ~$30.86/share
- • Anti-dilution adjustment provisions apply, meaning conversion rate (and dilution) could increase over time
Item 1.02 · Termination of a Material Definitive Agreement
- • Full prepayment of all outstanding principal, accrued interest, and fees under the Note Purchase Agreement on March 17, 2026
- • Facility originated November 4, 2024, with Piper Sandler Finance LLC as Administrative Agent; terminated same day as prepayment
- • Prepayment funded by proceeds from a separate Convertible Notes Offering, signaling a debt refinancing/restructuring event
- • Note Purchase Agreement had been amended as recently as January 26, 2026, suggesting prior covenant or structural issues before replacement
Other Indivior Pharmaceuticals, Inc. 8-K Filings
Get deeper insights on Indivior Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.